Drug guides stem cells to desired location, improving their ability to heal
The field of stem cell therapy has once again ushered in a major breakthrough: for the first time in history, people have guided stem cells directly into the designated location, and thus, we can see stem cells for the first time The effect of concentrated treatment.
The research was recently published in the journal Proceedings of the National Academy of Sciences (PNAS). As a magazine as famous as "Nature" and "Science", since its inception in 1914, "PNAS" has published a number of blockbuster research. And this research may be expected to open the door to a new world of stem cell therapy.
You know, with the deepening of the
research on the human body, cells are also considered to be one of the precious
resources of human beings. Among these precious resources, if there is a more
precious level, then stem cells are bound to be included.
One of the consequences of the decline in the quantity and quality of stem cells is the occurrence of aging and diseases, especially some irreversible damages, such as spinal cord injury, knee injury and some neurodegenerative diseases (such as Alzheimer's disease). Alzheimer's disease, also known as Alzheimer's disease), before stem cell therapy were some unsolved diseases. But the advent of stem cell therapy has opened a new door for these treatments.
There is also a feature of stem cells that needs to be mentioned here - that is, the "homing" property of stem cells, which can help stem cells drive themselves and reach the damaged part of the human body for repairing, which is also the magic of stem cell therapy.
After analysis, the researchers found an important substance: GPCR - this substance can guide stem cells to the damaged site well, and at the same time it does not trigger a serious inflammatory response, which is in line with a good guide It can lead everyone to the destination without disturbing the nearby residents. Based on this, the researchers created the SDV1a drug.
It can be seen that the design of the SDV1a drug is very clever (as shown in the figure above), on the one hand, it can guide stem cells to the damaged part to a greater extent, and play a repairing role as much as possible, on the other hand, it is also in the process of design. The part that causes the inflammatory response is cut off and the inflammatory response is reduced.
And this ingenious design means that it may be the nemesis of neurodegenerative diseases: in the brain, some inflammatory responses may attack other nerve cells, which may lead to some other diseases. And SDV1a drugs have the potential to solve this dilemma. This was also demonstrated in experiments in mice: In the adult mouse cortex, the SDV1a drug was better able to guide stem cells to their own site.
After 2 weeks, the mice were observed and found that the distribution of stem cells was consistent with the distribution of SDV1a drugs: SDV1a drugs could well guide stem cells to the site of treatment, and this effect was sustained, and the whole mice were The life cycle persisted, suggesting that SDV1a drugs could elicit stable, long-lasting, benign bootstrapping.
What's more, whether the stem cells are injected alone or the stem cells and SDV1a drugs are injected together, they will not cause an inflammatory response, which also ensures the safety of the treatment and prolongs the lifespan of the diseased mice during the treatment.
It can be said that this research may change the current treatment of many incurable diseases, including:Central nervous system repair;muscular dystrophy;Parkinson's disease;and many more......
Perhaps these diseases will lead to a major progress in treatment. In addition, we all know that an important side effect of CAR-T cell therapy is cytokine storm (CRS), and this study may also help to curb (CRS) production. Stem cell therapy, together with immune cell therapy, may also usher in a new era of cancer treatment.
CELL BIOTECHNOLOGY GROUP INC.